Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Tenapanor (KHK7791) in Hemodialysis Patients with Hyperphosphatemia
NCT04767581Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperphosphatemia comparing KHK7791 with Placebo (2 arms). Primary endpoint: Changes in serum phosphorous levels from baseline values at 8 weeks. Started Mar 2021; status: completed.
02
Drugs
tenapanor
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT04767581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04767581.